CYTK ▲ +0.4% - Cytokinetics, Incorporated
$CYTK - Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
30-SEP-2026 07:30 AM ET
Share this post
More filings for $CYTK
CYTK ▲ +0.8% - Cytokinetics, IncorporatedOct 19, 2026CYTK ▼ -0.2% - Cytokinetics, IncorporatedOct 12, 2026CYTK ▼ -1.5% - Cytokinetics, IncorporatedOct 8, 2026CYTK ▲ +0.0% - Cytokinetics, IncorporatedOct 2, 2026CYTK ▲ +0.6% - Cytokinetics, IncorporatedSep 2, 2026CYTK ▼ -6.3% - Cytokinetics, IncorporatedAug 29, 2026
View full $CYTK filing history →💬 Comments
Loading comments…
Leave a comment